TNF and acute myeloid leukemia: Supporting evidence from a clinical trial of a Smac mimetic, DEBIO1143, combined with daunorubicin and cytarabine in patients with acute myeloid leukemia (AML) revealed that the patients who responded more frequently showed an increase in plasma TNF-α levels [70].